Share This Page
Patent: 10,689,370
✉ Email this page to a colleague
Summary for Patent: 10,689,370
Title: | Cyclopropane carboxamide modulators of cystic fibrosis transmembrane conductance regulator |
Abstract: | The present invention relates to new cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator proteins, pharmaceutical compositions thereof, and methods of use thereof. ##STR00001## |
Inventor(s): | Zhang; Chengzhi (Frazer, PA), Chakma; Justin (Frazer, PA) |
Assignee: | AUSPEX PHARMACEUTICALS, INC. (North Wales, PA) |
Application Number: | 16/225,098 |
Patent Claims: | see list of patent claims |
Patent landscape, scope, and claims summary: | Comprehensive Analysis of United States Patent 10,689,370 IntroductionUnited States Patent 10,689,370, hereafter referred to as the '370 patent, is a patent that has been granted by the United States Patent and Trademark Office (USPTO). To conduct a comprehensive and critical analysis of this patent, we need to delve into various aspects including the patent's claims, its position within the patent landscape, potential risks and opportunities, and its implications for the industry. Patent Claims AnalysisClaim Structure and ScopeThe '370 patent includes a set of claims that define the scope of the invention. These claims are categorized into independent and dependent claims. Independent claims stand alone and define the invention broadly, while dependent claims build upon the independent claims and provide more specific details. Claim Validity and EnforceabilityTo assess the validity and enforceability of the claims, it is crucial to conduct a prior art search. This involves identifying existing technologies or innovations that may affect the novelty and non-obviousness of the invention. Effective patent analysis, as outlined by Evalueserve, includes examining patent citations, conducting prior art searches, and analyzing patent families to determine the geographical coverage and strength of the patent[5]. Obviousness-Type Double Patenting (ODP)In cases where multiple patents are related, as seen in the Cellect LLC case, the issue of obviousness-type double patenting (ODP) may arise. ODP analysis is critical to ensure that the claims do not overlap in a way that would render them unpatentable. The USPTO and the Federal Circuit have established guidelines on how to perform ODP analysis, particularly in relation to patent term adjustments and extensions[1]. Patent Landscape AnalysisCompetitive LandscapeAnalyzing the patent landscape involves identifying key players and competitors in the technology field. This includes examining their patent portfolios to assess their strengths and weaknesses. By categorizing patents using technology classifications, companies can better understand the competitive dynamics and potential barriers to entry[5]. Technology Trends and Time Series AnalysisPlotting patent filing trends over time helps in understanding the evolution of technology in the field. This analysis can identify peaks and valleys in innovation activity, providing insights into areas of high interest and potential white spaces for innovation[5]. Citation AnalysisExamining patent citations helps in understanding how the '370 patent relates to prior and subsequent innovations. This type of analysis can gauge the importance of the patent within its technological field and identify potential collaborators or competitors[5]. Valuation and Strategic ImplicationsIntellectual Property ValuationThe '370 patent, as part of a company's intellectual property portfolio, can represent significant value. Effective patent analysis helps in determining this value, which is crucial for licensing, mergers and acquisitions, or seeking investment. The valuation process considers factors such as the patent's novelty, non-obviousness, and market demand[5]. R&D Strategy and Risk MitigationBy analyzing the '370 patent and its position in the patent landscape, companies can refine their R&D strategies. This includes identifying areas where they should invest in new technologies, form partnerships, or license existing patents to achieve their business goals. It also involves identifying potential risks associated with their intellectual property strategy, such as patents that may be vulnerable to challenges[5]. Legal and Regulatory ComplianceDisclosure RequirementsThe use of AI tools in drafting patent applications, as highlighted by recent USPTO guidance, requires careful consideration. If AI tools contribute significantly to the invention, this must be disclosed to the USPTO to ensure compliance with patentability requirements[2]. Patent Assertion Entities (PAEs)The '370 patent could also be subject to assertion by Patent Assertion Entities (PAEs), which can significantly impact its value and enforceability. PAEs, as studied by the FTC, often engage in litigation or licensing activities that can affect the patent's validity and the financial burden on the patent holder[3]. Market Assessment and Technology TransferMarket DynamicsPatent analysis provides insights into the size and dynamics of a particular market. Understanding the competitive landscape and barriers to entry helps businesses make informed decisions about entering new markets or expanding existing ones. The '370 patent's position in this landscape can influence market strategies and technology transfer initiatives[5]. Technology TransferUniversities, research institutions, and companies often engage in technology transfer to commercialize their research. Patent analysis facilitates the identification of technologies with commercial potential, aiding in the transfer of knowledge and technologies from research settings to the marketplace[5]. Visualizations and Keyword AnalysisVisual RepresentationsCreating visualizations such as heat maps, network graphs, and trend charts can present findings in a visually compelling way. This helps in communicating complex patent data to stakeholders and making informed decisions[5]. Keyword AnalysisUsing natural language processing (NLP) and text mining techniques to analyze patent titles and abstracts for common keywords and trends can provide insights into the technological focus and innovation trends related to the '370 patent[5]. Key Takeaways
Frequently Asked Questions (FAQs)What is the importance of prior art searches in patent analysis?Prior art searches are essential to determine whether an invention is novel and non-obvious. This search helps identify existing technologies that may affect the validity or patentability of a new invention[5]. How does the use of AI tools impact patent applications?The use of AI tools in drafting patent applications must be disclosed to the USPTO if the AI contributions are material to patentability. Practitioners must verify the accuracy of factual assertions and ensure that AI contributions do not introduce inaccurate statements or omit material information[2]. What are the different types of Patent Assertion Entities (PAEs)?PAEs can be categorized into Portfolio PAEs and Litigation PAEs. Portfolio PAEs negotiate licenses covering large portfolios without first suing, while Litigation PAEs primarily file lawsuits to assert their patents[3]. How can patent analysis aid in R&D strategy?Patent analysis helps organizations refine their R&D strategies by identifying white spaces or areas with fewer patents, indicating potential opportunities for innovation. It also aids in identifying areas where companies should invest in new technologies or form partnerships[5]. What is the role of patent citations in analyzing a patent's importance?Patent citations help in understanding how a patent relates to prior and subsequent innovations. This analysis can gauge the importance of a patent within its technological field and identify potential collaborators or competitors[5]. Cited Sources:
More… ↓ |
Details for Patent 10,689,370
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Organon Usa Inc., A Subsidiary Of Merck & Co., Inc. | COTAZYM | pancrelipase | Capsule, Delayed Release | 020580 | December 09, 1996 | 10,689,370 | 2034-12-31 |
Abbvie Inc. | CREON | pancrelipase | Capsule, Delayed Release | 020725 | April 30, 2009 | 10,689,370 | 2034-12-31 |
Abbvie Inc. | CREON | pancrelipase | Capsule, Delayed Release | 020725 | June 10, 2011 | 10,689,370 | 2034-12-31 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |